These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 22402856

  • 1. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

  • 2. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 3. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 4. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 5. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.
    Expert Rev Neurother; 2011 Feb 04; 11(2):165-83. PubMed ID: 21158700
    [Abstract] [Full Text] [Related]

  • 6. Rebound of disease activity during pregnancy after withdrawal of fingolimod.
    Sempere AP, Berenguer-Ruiz L, Feliu-Rey E.
    Eur J Neurol; 2013 Aug 04; 20(8):e109-10. PubMed ID: 23829238
    [No Abstract] [Full Text] [Related]

  • 7. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
    Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C.
    Neurology; 2009 Mar 17; 72(11):1022-4. PubMed ID: 19289744
    [No Abstract] [Full Text] [Related]

  • 8. Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Huys AC, Lalive PH, Sekoranja L.
    Mult Scler; 2014 Apr 17; 20(5):636-7. PubMed ID: 23897641
    [No Abstract] [Full Text] [Related]

  • 9. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S, von Andrian UH.
    N Engl J Med; 2006 Sep 14; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract] [Full Text] [Related]

  • 10. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 14; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 11. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013 May 14; 129(5):548-9. PubMed ID: 23520898
    [Abstract] [Full Text] [Related]

  • 12. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T.
    Arch Neurol; 2012 Feb 14; 69(2):262-4. PubMed ID: 22332194
    [Abstract] [Full Text] [Related]

  • 13. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 14; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 14. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L.
    Ideggyogy Sz; 2014 Mar 30; 67(3-4):141. PubMed ID: 26118259
    [No Abstract] [Full Text] [Related]

  • 15. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 30; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 16. Sudden unexpected death on fingolimod.
    Lindsey JW, Haden-Pinneri K, Memon NB, Buja LM.
    Mult Scler; 2012 Oct 30; 18(10):1507-8. PubMed ID: 22300970
    [No Abstract] [Full Text] [Related]

  • 17. [Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
    Jakab G.
    Ideggyogy Sz; 2012 May 30; 65(5-6):207-8. PubMed ID: 22724290
    [No Abstract] [Full Text] [Related]

  • 18. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May 30; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 19. [2012: Update on diagnosis and treatment of multiple sclerosis].
    Havla J, Kümpfel T, Hohlfeld R.
    Dtsch Med Wochenschr; 2012 Apr 30; 137(17):894-9. PubMed ID: 22492476
    [No Abstract] [Full Text] [Related]

  • 20. Update on multiple sclerosis treatments.
    Bridel C, Lalive PH.
    Swiss Med Wkly; 2014 Apr 30; 144():w14012. PubMed ID: 25247669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.